Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Roche Holding AG (RO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
389.80 +2.60    +0.67%
11:31:00 - Closed. Currency in CHF ( Disclaimer )
Type:  Equity
Market:  Switzerland
ISIN:  CH0012032113 
VALOR:  1203211
  • Volume: 32,609
  • Bid/Ask: 389.60 / 389.80
  • Day's Range: 386.20 - 390.40
Roche Holding 389.80 +2.60 +0.67%
RankUsernameTotalClosedWinningWin %Chg. %
1Frans Lambrechts111100+8.75%
2Nacho Fdez111100+6.49%
3Claude Mazza111100+5.16%
4Marco Barbosa111100+3.88%
5Igor Mavriky111100+3.71%
6Thomas Strasser111100+3.66%
7Claude Danant222100+3.62%
8Mikhail Gorbunov222100+3.39%
9Ejvind Byskov111100+3.08%
10Alessandro Denini111100+2.79%
11jordi perez111100+2.72%
12Alexandre Caillet111100+2.56%
13Irene Schneider111100+2.46%
14Francisco Gonzalez111100+2.41%
15Agustin Vicente111100+2.24%
16Philippe Szerer222100+2.21%
17Lorenzo Buell111100+2.19%
18Dongliang Yin111100+2.17%
19Kaushik Shah111100+2.17%
20Xavier En Re Menor111100+2.15%
21Ali Abdelfatah1000+1.76%
22Robyn Hood111100+1.7%
23Ivan Mora Llesuy111100+1.69%
24Ernesto Scettrini111100+1.45%
25Massimo Cavalletti111100+1.21%
26Frances Roschi22150+1.19%
27Quentin Georges111100+1.09%
28Cesare Deorsola111100+1%
29zinvest1000+0.8%
30Didier Kasse1000+0.74%
31Adriano Benzoni111100+0.69%
32António Paiva111100+0.57%
33Andrés Caldelari111100+0.52%
34ziya yılmaz111100+0.41%
35Billy Hanafi111100+0.4%
36Mariana Lienhard1000+0.33%
37Martin Jehli111100+0.15%
38Νικοσ Σαρλησ11000%
39Hugo Martin11000%
40Marco Sobrero11000%
41Cesare Lori11000%
42Kursat Balaydin1100-0.28%
43Ivan Dimitrov1100-0.61%
44Bernard Radvaner1100-0.9%
45Philipp Goedecke1000-0.99%
46Ferri Golf1100-1.55%
47Myro Pñr22150-1.66%
48Inés Pastor Martínez1100-1.93%
49Dries Verbruggen1100-2.41%
50Daniel Casas1100-2.47%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RO Comments

Write your thoughts about Roche Holding AG
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Sherlyn Jones
Sherlyn Jones Apr 22, 2021 6:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
Ruta Rublevska
Ruta Rublevska Nov 16, 2020 3:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
13.11.2020. CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza. This CHMP recommendation brings patients with influenza one step closer to potentially benefiting from Xofluza’s oral one-dose regimen, setting adults and adolescents on the path to feeling better sooner compared to placebo,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe that access to effective antivirals for influenza, and particularly their use in the prophylactic setting, could help reduce the strain of the COVID-19 pandemic on healthcare systems in Europe.
Jonny Tr
Jonny Tr May 04, 2020 8:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Just like Biolidics. they get approval for Covid19 tests kits in USA
Billy Hanafi
Billy Hanafi Jan 25, 2019 10:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i dont know
edgard hajjar
edgard hajjar May 07, 2018 5:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
is the historical price adjusted for stock splits?
Billy Hanafi
Billy Hanafi May 07, 2018 5:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i dont know
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email